{"schema_version":"secwatch.filing_event.v1","accession":"0001384101-26-000049","form_type":"8-K","ticker":"VCYT","cik":"0001384101","company_name":"VERACYTE, INC.","filed_at":"2026-09-14T20:07:12+00:00","discovered_at":"2026-09-14T20:08:24.456316+00:00","generated_at":"2026-09-14T20:08:30.310188+00:00","sec_items":["1.01","2.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Veracyte acquires Convergent Genomics for $150M cash plus $30M milestones","bullets":["Veracyte paid $150M upfront cash for Convergent, plus up to $30M milestone payments tied to UroAmp publications and reimbursement.","Adds UroAmp urinary tumor DNA (utDNA) platform for bladder cancer, clinically validated in NMIBC for therapy monitoring and surveillance.","Veracyte expects to commercialize initial UroAmp test in late 2028, subject to reimbursement timelines; plans additional indications.","RUMBLE study: utDNA-positive patients post-BCG had 12-month recurrence-free survival 25% vs 91% for utDNA-negative patients.","Veracyte maintains 2026 adjusted EBITDA guidance, including Convergent's ongoing operating expenses."],"urls":{"canonical":"https://secwatch.observer/filing/0001384101-26-000049","json":"https://secwatch.observer/filing/0001384101-26-000049.json","markdown":"https://secwatch.observer/filing/0001384101-26-000049.md","text":"https://secwatch.observer/filing/0001384101-26-000049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1384101/000138410126000049/0001384101-26-000049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1384101/000138410126000049/vcyt-20260910.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-14T20:08:30.310188+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}